Amryt Pharma Overview

  • Founded
  • 2004
Founded
  • Status
  • Public
  • Employees
  • 88
Employees
  • Stock Symbol
  • AMYT
Stock Symbol
  • Investments
  • 4
  • Share Price
  • $2.80
  • (As of Friday Closing)

Amryt Pharma General Information

Description

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Contact Information

Formerly Known As
Amryt Pharmaceuticals Designated Activity Company
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Stock Exchange
LON
Primary Office
  • Ivybridge House
  • 1 Adam Street
  • London WC2N 6LE
  • England, United Kingdom
+44 020 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amryt Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.80 $2.80 $0.98 - $3.24 $501M 179M 65.3K -$0.54

Amryt Pharma Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 541,271 268,107 59,680 73,537
Revenue 180,381 58,124 17,095 14,411
EBITDA (28,506) (45,717) (28,479) (28,238)
Net Income (89,795) (65,535) (30,487) (29,475)
Total Assets 507,435 534,347 80,834 96,084
Total Debt 185,821 178,466 19,011 12,720
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amryt Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amryt Pharma‘s full profile, request access.

Request a free trial

Amryt Pharma Executive Team (8)

Name Title Board Seat Contact Info
Joseph Wiley MD Founder, Chief Executive Officer & Board Member
David Allmond Chief Commercial Officer
Rory Nealon Secretary, Administration
Stephen Joyce Vice President, Global Marketing
Mark Sumeray Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Amryt Pharma Board Members (10)

Name Representing Role Since
00000 00000 00.0 Self Board Member 000 0000
000000 00000 00 Amryt Pharma Board Member 000 0000
000000 00000 00 Amryt Pharma Founder, Chief Executive Officer & Board Member 000 0000
0000000 0000 00 Amryt Pharma Board Member 000 0000
0000000 00000 Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Amryt Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amryt Pharma Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 24-Sep-2019 000000000000000000 00000 Biotechnology 000000 00000 00
000000 (0000000) 18-Apr-2016 000000000000000000 000.00 Drug Discovery
0000000 000000 18-Apr-2016 000000000000000000 000.00 Energy Exploration
SomPharmaceuticals 18-Apr-2016 Merger/Acquisition 00.000 Therapeutic Devices
To view Amryt Pharma’s complete acquisitions history, request access »